After about 25,000 hours studying cancer metabolism since 2017, I have collected a set of complementary strategies that I would want to use if I were diagnosed with cancer. They range from daily habits to dietary approaches, drugs and supplements. They do not all have the same evidence, purpose or risk.
Changing the metabolic environment of a tumor could affect much more than its ATP supply. In our proposed Therapeutic Hypoglycemia approach, the aim is to reduce glucose and glutamine availability while increasing ketones and modifying buffering. The interesting question is how these changes interact across different cell types.
A small glioblastoma study included eighteen patients. Three-year survival was reported in 4 of 6 who maintained the ketogenic diet for more than six months, compared with 1 of 12 who did not. Selection and survival bias affect this comparison; it does not show that the diet caused the difference.
In glycolytic tumor regions, lactate production and acid handling contribute to an acidic, immunosuppressive tumor environment. Local lactate concentration and pH also depend on transport, buffering and clearance.
Tumor-infiltrating T cells must fight cancer in an environment where glucose is often scarce. An important question is whether ketones can sustain their ability to kill cancer cells when glucose availability is severely restricted.